In the second-line setting, based on the results from the phase II KEYNOTE-158 (NCT02628067), pembrolizumab gained FDA approval as treatment for patients with PD-L1-positive cervical cancer (CPS of ≥1) in 2018 [175]. This evidence concerns the gene CD274 and cervical carcinoma.